The company has domestic leading core technology platforms such as plasmid DNA production, lentivirus vector production, car-t molecular design / verification / production, quality control of cellular drugs and perfect quality assurance system. Based on these platform technologies, two preclinical studies of dual target car-t cell drugs for blood tumors were completed. The company also has a layout in solid tumors and has a variety of highly innovative car-t R & D projects for solid tumors.